Adicet Bio to Present at the Jefferies Cell Therapy Summit
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases, today announced that Chen Schor,
President and Chief Executive Officer of Adicet Bio, and Stewart
Abbot, Ph.D., Chief Scientific and Operating Officer of Adicet Bio,
will participate in a fireside chat at the Jefferies Cell Therapy
Summit on Monday, October 5, 2020 at 2:30 PM ET.
A live audio webcast of the fireside chat can be accessed on the
Investors section of Adicet Bio’s website at
https://investor.adicetbio.com. An archived replay will be
available for 30 days following the presentation.
About Adicet Bio, Inc.Adicet Bio, Inc. is a
biotechnology company discovering and developing allogeneic gamma
delta T cell therapies for cancer and other diseases. Adicet is
advancing a pipeline of “off-the-shelf” gamma delta T cells,
engineered with chimeric antigen receptors and T cell receptor-like
antibodies to enhance selective tumor targeting, facilitate innate
and adaptive anti-tumor immune response, and improve persistence
for durable activity in patients. For more information, please
visit our website at http://www.adicetbio.com.
Adicet Bio, Inc.Investor and Media
Janhavi MohiteStern Investor Relations,